论文部分内容阅读
目的:研究p53、ER和PR在子宫内膜癌的表达及其临床意义。方法:应用免疫组化技术对56例子宫内膜癌组织进行检测,结合临床病理学指标进行分析。结果:p53、ER和PR在56例子宫内膜癌的阳性表达率分别是44.6 %,66.1 %和64.3 %。p53的阳性表达率在子宫内膜癌的不同临床分期和组织学分级均有显著性差异(P<0.05)。ER、PR在子宫内膜癌的阳性表达率与组织学分级密切相关,在组织分化好的阳性表达率显著高于组织分化差的阳性表达率(P<0.05)。结论:p53在子宫内膜癌的发生、发展中起着重要的调控作用。ER、PR的缺失表达与子宫内膜癌的恶性程度密切相关,对分析子宫内膜癌的预后和指导临床内分泌治疗均有重要意义。
Objective: To study the expression of p53, ER and PR in endometrial carcinoma and its clinical significance. Methods: 56 cases of endometrial carcinoma were detected by immunohistochemistry and analyzed with clinicopathological parameters. Results: The positive rates of p53, ER and PR in 56 cases of endometrial carcinoma were 44.6%, 66.1% and 64.3% respectively. The positive rate of p53 in different clinical stages and histological grade of endometrial carcinoma were significantly different (P <0.05). The positive expression rates of ER and PR in endometrial carcinoma were closely related to the histological grade. The positive expression rates of ER and PR in well differentiated tissues were significantly higher than those in poorly differentiated tissues (P <0.05). Conclusion: p53 plays an important regulatory role in the development and progression of endometrial cancer. The lack of expression of ER and PR is closely related to the degree of malignancy of endometrial cancer, which is of great significance for the analysis of the prognosis of endometrial cancer and the guidance of clinical endocrine therapy.